AMP-activated protein kinase as a drug target

被引：344

作者：

Hardie, D. Grahame ^{[1
]}

机构：

[1] Univ Dundee, Div Mol Physiol, Dundee DD1 5EH, Scotland

来源：

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY | 2007年 / 47卷

基金：

英国惠康基金;

关键词：

metformin; biguanides; thiazolidinediones; obesity; diabetes;

D O I：

10.1146/annurev.pharmtox.47.120505.105304

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The AMP-activated protein kinase (AMPK) system is a regulator of energy balance at both the cellular and whole-body levels that, once activated by low energy status, effects a switch from ATP-consuming anabolic pathways to ATP-producing catabolic pathways. It now appears to be the major target for two existing classes of drug used to treat type 2 diabetes, i.e., the biguanides and thiazolidinediones. However, in both cases these activate AMPK indirectly, and an interesting question concerns whether a drug that directly activated AMPK would retain the therapeutic benefits of the existing drugs while eliminating unwanted side effects. AMPK activators also now have potential as anticancer drugs.

引用

页码：185 / 210

页数：26

共 164 条

[11] MODULATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE-ACTIVITY WITH CAMP AND WITH PROTEIN FRACTIONS OF RAT-LIVER CYTOSOL [J].

BEG, ZH ;

ALLMANN, DW ;

GIBSON, DM .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1973, 54 (04) :1362-1369

[12] Effect of 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats [J].

Bergeron, R ;

Previs, SF ;

Cline, GW ;

Perret, P ;

Russell, RR ;

Young, LH ;

Shulman, GI .

DIABETES, 2001, 50 (05) :1076-1082

[13] The AMP-activated protein kinase prevents ceramide synthesis de novo and apoptosis in astrocytes [J].

Blázquez, C ;

Geelen, MJH ;

Velasco, G ;

Guzmán, M .

FEBS LETTERS, 2001, 489 (2-3) :149-153

[14] AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. [J].

Bolster, DR ;

Crozier, SJ ;

Kimball, SR ;

Jefferson, LS .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (27) :23977-23980

[15] Analysis of the LKB1-STRAD-MO25 complex [J].

Boudeau, J ;

Scott, JW ;

Resta, N ;

Deak, M ;

Kieloch, A ;

Komander, D ;

Hardie, DG ;

Prescott, AR ;

van Aalten, DMF ;

Alessi, DR .

JOURNAL OF CELL SCIENCE, 2004, 117 (26) :6365-6375

[16] LKB1, a protein kinase regulating cell proliferation and polarity [J].

Boudeau, J ;

Sapkota, G ;

Alessi, DR .

FEBS LETTERS, 2003, 546 (01) :159-165

[17] Increased cancer-related mortality for patients with type 2 diabetes who use sulforrylureas or insulin [J].

Bowker, SL ;

Majumdar, SR ;

Veugelers, P ;

Johnson, JA .

DIABETES CARE, 2006, 29 (02) :254-258

[18] Thiazolidinediones, like metformin, inhibit respiratory complex I -: A common mechanism contributing to their antidiabetic actions? [J].

Brunmair, B ;

Staniek, K ;

Gras, F ;

Scharf, N ;

Althaym, A ;

Clara, R ;

Roden, M ;

Gnaiger, E ;

Nohl, H ;

Waldhäusl, W ;

Fürnsinn, C .

DIABETES, 2004, 53 (04) :1052-1059

[19] Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome [J].

Buhl, ES ;

Jessen, N ;

Pold, R ;

Ledet, T ;

Flyvbjerg, A ;

Pedersen, SB ;

Pedersen, O ;

Schmitz, O ;

Lund, S .

DIABETES, 2002, 51 (07) :2199-2206

[20] Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the γ2-subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency [J].

Burwinkel, B ;

Scott, JW ;

Bührer, C ;

van Landeghem, FKH ;

Cox, GF ;

Wilson, CJ ;

Hardie, DG ;

Kilimann, MW .

AMERICAN JOURNAL OF HUMAN GENETICS, 2005, 76 (06) :1034-1049

← 1 2 3 4 5 6 7 8 9 10 →